Cargando…

Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis

Introduction: Pseudomonas aeruginosa (PA) is a leading cause of healthcare-associated infections. A variety of antibiotic classes are used in the treatment of PA infections, including beta-lactams (BLs) and fluoroquinolones (FQs), given either together in combination therapy or alone in monotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Reid, Eric, Walters, Ryan W., Destache, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698261/ https://www.ncbi.nlm.nih.gov/pubmed/34943695 http://dx.doi.org/10.3390/antibiotics10121483

Ejemplares similares

129. Beta-lactam vs Fluoroquinolone Monotherapy for pseudomonas Aeruginosa infection: A Systematic Review and Meta-analysis
por: Reid, Eric C, et al.
Publicado: (2020)

Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an Aminoglycoside or a Quinolone for Pseudomonas aeruginosa Bacteremia
por: Bliziotis, Ioannis A., et al.
Publicado: (2011)

Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis
por: Liu, Sitong, et al.
Publicado: (2019)

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use
por: MacDougall, Conan, et al.
Publicado: (2005)

Effectiveness of empiric aztreonam compared to other beta-lactams for treatment of Pseudomonas aeruginosa infections
por: Hogan, Michael, et al.
Publicado: (2018)

Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa
por: Zhao, Lei, et al.
Publicado: (2020)

In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
por: Spottiswoode, Natasha, et al.
Publicado: (2023)

165. Comparative Effectiveness of Oral Fluoroquinolones vs. β-Lactams for the Treatment of Patients with Enterobacteriaceae Bloodstream Infections
por: Bjork, Lauren, et al.
Publicado: (2019)

Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis
por: Punjabi, Chitra, et al.
Publicado: (2019)

Plasmid-Mediated Fluoroquinolone Resistance in Pseudomonas aeruginosa and Acinetobacter baumannii
por: Venkataramana, Geetha P., et al.
Publicado: (2022)

1114. Effectiveness and Safety of Beta-lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2021)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams
por: Bolhuis, Mathieu S., et al.
Publicado: (2011)

271. Clinical Outcomes Treating Gram-Negative Bacteremia with Oral Beta-Lactams vs. Trimethoprim-Sulfamethoxazole or Fluoroquinolone Step-Down Therapy
por: Sinclair, Emily, et al.
Publicado: (2020)

277. Comparison of Oral Beta-Lactams and Fluoroquinolones for Step-Down in Uncomplicated Enterobacterales Blood Stream Infections
por: Ngo, Nichol, et al.
Publicado: (2020)

185. Pseudomonas aeruginosa (PA) Bacteremia and Patient Outcome during COVID-19 Pandemic
por: Vivekanandan, Renuga, et al.
Publicado: (2023)

Potential Synergistic Antibiotic Combinations against Fluoroquinolone-Resistant Pseudomonas aeruginosa
por: Kothari, Ashish, et al.
Publicado: (2022)

In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa
por: Lomovskaya, Olga, et al.
Publicado: (2021)

Fluoroquinolone and beta-lactam antimicrobials induce different transcriptome profiles in Salmonella enterica persister cells
por: Mattiello, S. P., et al.
Publicado: (2023)

1297. Azithromycin vs Beta Lactams in Acute Exacerbations of COPD
por: Kale-Pradhan, Pramodini, et al.
Publicado: (2021)

β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
por: Glen, Karl A., et al.
Publicado: (2021)

Dual β-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibition
por: Siriyong, Thanyaluck, et al.
Publicado: (2019)

308. Re-purposing Beta-lactam Antibiotics as Fluoroquinolone Sparing Stepdown Therapy for the Treatment of Enterobacteriales Bloodstream Infections
por: Davis, Matthew, et al.
Publicado: (2020)

Intra-ocular Predation of Fluoroquinolone-Resistant Pseudomonas aeruginosa and Serratia marcescens by Predatory Bacteria
por: Romanowski, Eric G., et al.
Publicado: (2023)

Comparative-Effectiveness of Oral Beta-Lactams and Fluoroquinolones for Stepdown Therapy in Patients with Enterobacterales Bloodstream Infections: A Retrospective Cohort Study
por: Bjork, Lauren, et al.
Publicado: (2023)

Correlation Between Virulence Genotype and Fluoroquinolone Resistance in Carbapenem-Resistant Pseudomonas aeruginosa
por: Cho, Hye Hyun, et al.
Publicado: (2014)

Detection of Overexpression of Efflux Pump Expression in Fluoroquinolone-Resistant Pseudomonas aeruginosa Isolates
por: Al Rashed, Nouf, et al.
Publicado: (2020)

Association between Consumption of Fluoroquinolones and Carbapenems and Their Resistance Rates in Pseudomonas aeruginosa in Argentina
por: Boni, Silvia, et al.
Publicado: (2022)

181 Empiric Coverage of ICU Patients for Infections Due to Beta-lactam Resistant Pseudomonas aeruginosa with Combination Therapy: A Needs Assessment
por: Cawcutt, Kelly, et al.
Publicado: (2014)

Exploring antimicrobial resistance to beta-lactams, aminoglycosides and fluoroquinolones in E. coli and K. pneumoniae using proteogenomics
por: Foudraine, Dimard E., et al.
Publicado: (2021)

2269. Clinical Outcomes in Patients with Carbapenem-Non-Susceptible, β-Lactam-Susceptible Pseudomonas aeruginosa Infections
por: Gavaghan, Victoria M, et al.
Publicado: (2019)

Carbapenems vs β-Lactam Monotherapy or Combination Therapy for the Treatment of Complicated Intra-abdominal Infections: Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Li, Yan, et al.
Publicado: (2019)

High prevalence of bla(VEB), bla(GES) and bla(PER) genes in beta-lactam resistant clinical isolates of Pseudomonas aeruginosa
por: Haghighi, Saboura, et al.
Publicado: (2022)

Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against Pseudomonas aeruginosa
por: Dhiman, Shiv, et al.
Publicado: (2023)

1600. Susceptibility of β-Lactam-Resistant Pseudomonas aeruginosa to Other β-Lactams: Is There Truly a Lack of Cross-Resistance?
por: Patel, Twisha S, et al.
Publicado: (2019)

Tackling recalcitrant Pseudomonas aeruginosa infections in critical illness via anti-virulence monotherapy
por: Singh, Vijay K., et al.
Publicado: (2022)

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa
por: Kosai, Kosuke, et al.
Publicado: (2018)

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa
por: Kosai, Kosuke, et al.
Publicado: (2017)

Loss of membrane‐bound lytic transglycosylases increases outer membrane permeability and β‐lactam sensitivity in Pseudomonas aeruginosa
por: Lamers, Ryan P., et al.
Publicado: (2015)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_75531n2hc77h9jkn0icvbsi2dl